logo-loader
NASDAQ:AVXL

Anavex Life Sciences

Receive alerts
Market:
NASDAQ
Market Cap:
$142.68 m
Price
$2.71
Change
8.40%
52 weeks high
4.08
52 weeks low
1.25

Viewing results 1-9 of 9

Health

Anavex Life Sciences doses patients in Phase 2 ANAVEX2-73 Parkinson disease dementia study

The biotech also has clinical programs for the drug for the treatment of Alzheimer’s disease and Rett Syndrome, a rare neurological disorder that occurs mainly in girls...

on 12/13/2018
Health

Anavex Life Sciences shares rise after FDA gives green light on Phase 2 trial

Its drug Anavex2-73 is being developed to treat Rett Syndrome, a rare neurological disorder that occurs mainly in girls and can lead to severe impairments...

on 10/19/2018
Health

Neurotrope and Anavex are 'making progress' with Alzheimer's programs, says Maxim Group

Experts are optimistic biotechs may be turning the corner on the mind-robbing disease after years of failure...

on 07/27/2018
Health

Anavex Life Sciences gets go-ahead from Spain to begin trial for its Parkinson's disease treatment

Its Phase 2 trial of Anavex 2-73 kicks off in Spain in the coming months...

on 07/09/2018
Health

Anavex Life's Alzheimer's drug awarded orphan status for child seizures

Anavex 2-73 is the company’s lead candidate and currently in a Phase 2a clinical trial for Alzheimer’s disease. ...

on 06/22/2016
Health

Anavex Life Sciences Corp unveils positive pre-clinical data on Alzheimer’s candidate

Anavex Life Sciences Corp said pre-clinical data from its candidate ANAVEX 3-71 reinforced its belief it could be a treatment for the cognitive disease Alzheimer's. ...

on 03/14/2016
Health

Anavex Life shares advance on positive data for ANAVEX 2-73

Shares of Anavex Life Science rise more than 5% after the clinical-stage biopharmaceutical company reported positive data of ANAVEX 2-73 in an exploratory study in a Rett syndrome model...

on 02/25/2016
Health

Anavex to advance Alzheimer’s drug with larger Phase 2/3 trial

It comes as the US FDA provided Anavex with guidance on its proposed strategy for the drug candidate....

on 11/18/2015